A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

BACKGROUND: Cabozantinib inhibits pathways involved in medullary thyroid cancer (MTC). Cabozantinib is approved as 140 mg/day in capsules for MTC and 60 mg/day in tablets for other solid tumors. This study compared the two doses in progressive metastatic MTC. METHODS: In this Phase 4, randomized, do...

Descripción completa

Detalles Bibliográficos
Autores principales: Capdevila, Jaume, Klochikhin, Arkadiy, Leboulleux, Sophie, Isaev, Pavel, Badiu, Corin, Robinson, Bruce, Hughes, Brett G.M., Keam, Bhumsuk, Parnis, Francis, Elisei, Rossella, Gajate, Pablo, Gan, Hui K., Kapiteijn, Ellen, Locati, Laura, Mangeshkar, Milan, Faoro, Leonardo, Krajewska, Jolanta, Jarzab, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Thyroid Cancer and Nodules
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145260/
https://www.ncbi.nlm.nih.gov/pubmed/35403447
http://dx.doi.org/10.1089/thy.2022.0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145260/
https://www.ncbi.nlm.nih.gov/pubmed/35403447
http://dx.doi.org/10.1089/thy.2022.0027

Ejemplares similares